Form 8-K - Current report:
SEC Accession No. 0001714899-25-000054
Filing Date
2025-01-13
Accepted
2025-01-13 08:03:25
Documents
15
Period of Report
2025-01-13
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20250113.htm   iXBRL 8-K 31802
2 EX-99.1 ex991pressrelease1132025.htm EX-99.1 31515
6 denali_txlogox02.jpg GRAPHIC 680367
  Complete submission text file 0001714899-25-000054.txt   1123439

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20250113.xsd EX-101.SCH 1815
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20250113_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20250113_pre.xml EX-101.PRE 12530
17 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20250113_htm.xml XML 2730
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 25524886
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)